Conteduca, VincenzaJayaram, AnuradhaRomero-Laorden, NuriaWetterskog, DanielSalvi, SamantaGurioli, GiorgiaScarpi, EmanuelaCastro, ElenaMarin-Aguilera, MercedesLolli, CristianSchepisi, GiuseppeMaugeri, AntonioWingate, AnnaFarolfi, AlbertoCasadio, ValentinaMedina, AnaPuente, JavierVidal, Mª José MéndezMorales-Barrera, RafaelVilla-Guzmán, Jose CHernando, SusanaRodriguez-Vida, AlejoGonzález-Del-Alba, AránzazuMellado, BegoñaGonzalez-Billalabeitia, EnriqueOlmos, DavidAttard, GerhardtDe Giorgi, Ugo2023-01-252023-01-252018-10-26http://hdl.handle.net/10668/13576Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR]=1.61, 95% confidence interval [CI]=1.08-2.39, p=0.018), but not PFS (HR=1.04, 95% CI 0.74-1.46, p=0.8) or PSA response (odds ratio=1.14, 95% CI=0.65-1.99, p=0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Androgen receptorAndrogen receptor–directed therapiesBiomarkerCastration-resistant prostate cancerDocetaxelPlasma DNAAndrogen AntagonistsAndrostenesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesDocetaxelHumansKallikreinsMaleNeoplasm MetastasisNitrilesPhenylthiohydantoinProgression-Free SurvivalProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenSpainTime Factorsresearch article30773204open access10.1016/j.eururo.2018.09.0491873-7560PMC6377278https://doi.org/10.1016/j.eururo.2018.09.049https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377278/pdf